VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
CSL Limited vs GSK plc
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
CSL Limited
CSL · ASX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
GSK plc
GSK · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: CSL Limited leads (77 / 100 vs 62 / 100 for GSK plc).
- Segment focus: CSL Limited has 3 segments (71.7% in CSL Behring); GSK plc has 3 segments (37.6% in Specialty Medicines).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: CSL Limited has 7 moat types across 3 domains; GSK plc has 4 across 3.
Primary market context
CSL Limited
CSL Behring
Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases
Global
Hospitals, specialty pharmacies, physicians; payers and national health systems
Vertically integrated biopharma (plasma collection -> fractionation/manufacturing -> commercial distribution)
71.7%
GSK plc
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
Global
Hospitals, specialist physicians, payers
Innovator & branded manufacturer
37.6%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
CSL Limited strengths
GSK plc strengths
Segment mix
CSL Limited segments
Full profile >CSL Behring
Oligopoly
CSL Seqirus
Oligopoly
CSL Vifor
Oligopoly
GSK plc segments
Full profile >Vaccines
Oligopoly
Specialty Medicines
Oligopoly
General Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.